Substrats De Bêta-Lactamases Et Leurs Procédés D'utilisation Dans Le Diagnostic De La Tuberculose

J. Rao,Hexin Xie,Jeffrey D. Cirillo,James C. Sacchettini

2013-01-01

Abstract:L'invention concerne des substrats de β-Lactamases et des procedes d'utilisation des substrats pour detecter des β-lactamases et diagnostiquer la tuberculose.

What problem does this paper attempt to address?

High-throughput fluorescent screening of β-lactamase inhibitors to improve antibiotic treatment strategies for tuberculosis

Fei Yan,Shengui He,Xiuyan Han,Jiayue Wang,Xiangge Tian,Chao Wang,Jingnan Cui,Xiaochi Ma,Lei Feng,Tony D. James

DOI: https://doi.org/10.1016/j.bios.2022.114606

IF: 12.545

2022-11-15

Biosensors and Bioelectronics

Abstract:Tuberculosis (TB) is an infectious disease caused by Mycobacterium tuberculosis (Mtb), which is a major threat to global public health. Currently, β-lactam antibiotics are rarely used in the treatment of TB, since Mtb naturally expresses β-lactamase (Blac) which renders Mtb resistant to such antibiotics due to β-lactam cleavage. Fortunately, antibiotic resistance can be overcome when β-lactam antibiotics are combined with a Blac inhibitor. With the current research, a near-infrared fluorescent probe LXMB was developed for the real-time detection and imaging of endogenous Blac activity in Mtb. Furthermore, a high-throughput screening platform was established using LXMB to screen Blac inhibitors from herbal medicines. Guided by the visual bioassay, Tannic acid was isolated from Galla Chinensis as a potential Blac inhibitor and was further evaluated in combination with several β-lactam antibiotics which resulted in an enhanced inhibitory effect toward M. tuberculosis H37Ra. Finally, LXMB was used to label live M. tuberculosis H37Ra phagocytosed within macrophages. Consequently, LXMB was a useful fluorescent tool to explore the mechanism of drug resistance based on Blac and can assist in the development of new tuberculosis treatments.

biotechnology & applied microbiology,biophysics,chemistry, analytical,electrochemistry,nanoscience & nanotechnology
Compositions et procédés visant à potentialiser une activité antibiotique

Guillaume Cottarel,Timothy S. Gardner,Xiaoguang Lei,John Porco,Scott E. Schaus,Jamey Wierzbowski,Kollol Pal

2007-01-01

Abstract:L'invention concerne des composes qui potentialisent l'activite d'agents antibiotiques, en particulier des quinolones, notamment la norflaxine. L'invention concerne egalement des compositions, par exemple des compositions pharmaceutiques, comprenant les composes de l'invention. L'invention concerne egalement des compositions comprenant un antibiotique (par exemple, une quinolone) et un compose qui potentialise l'activite de cet antibiotique. L'invention concerne encore des procedes de traitement d'un sujet consistant a administrer un compose quelconque de l'invention ou une composition quelconque de l'invention a ce sujet. En outre, l'invention concerne des procedes de criblage visant a identifier des composes qui potentialisent l'activite d'un antibiotique, par exemple, une quinolone.
Rapid point-of-care detection of the tuberculosis pathogen using a BlaC-specific fluorogenic probe

Hexin Xie,Joseph Mire,Ying Kong,MiHee Chang,Hany A. Hassounah,Chris N. Thornton,James C. Sacchettini,Jeffrey D. Cirillo,Jianghong Rao

DOI: https://doi.org/10.1038/nchem.1435

IF: 24.274

2012-01-01

Nature Chemistry

Abstract:Early diagnosis of tuberculosis can dramatically reduce both its transmission and the associated death rate. The extremely slow growth rate of the causative pathogen, Mycobacterium tuberculosis ( Mtb ), however, makes this challenging at the point of care, particularly in resource-limited settings. Here we report the use of BlaC (an enzyme naturally expressed/secreted by tubercle bacilli) as a marker and the design of BlaC-specific fluorogenic substrates as probes for Mtb detection. These probes showed an enhancement by 100–200 times in fluorescence emission on BlaC activation and a greater than 1,000-fold selectivity for BlaC over TEM-1 β-lactamase, an important factor in reducing false-positive diagnoses. Insight into the BlaC specificity was revealed by successful co-crystallization of the probe/enzyme mutant complex. A refined green fluorescent probe ( CDG-OMe ) enabled the successful detection of live pathogen in less than ten minutes, even in unprocessed human sputum. This system offers the opportunity for the rapid, accurate detection of very low numbers of Mtb for the clinical diagnosis of tuberculosis in sputum and other specimens.
Fluorogenic Probes with Substitutions at the 2 and 7 Positions of Cephalosporin Are Highly BlaC‐Specific for Rapid Mycobacterium Tuberculosis Detection

Yunfeng Cheng,Hexin Xie,Preeti Sule,Hany Hassounah,Edward A Graviss,Ying Kong,Jeffrey D Cirillo,Jianghong Rao

DOI: https://doi.org/10.1002/anie.201405243

2014-01-01

Angewandte Chemie

Abstract:AbstractCurrent methods for the detection of Mycobacterium tuberculosis (Mtb) are either time consuming or require expensive instruments and are thus are not suitable for point‐of‐care diagnosis. The design, synthesis, and evaluation of fluorogenic probes with high specificity for BlaC, a biomarker expressed by Mtb, are described. The fluorogenic probe CDG‐3 is based on cephalosporin with substitutions at the 2 and 7 positions and it demonstrates over 120 000‐fold selectivity for BlaC over TEM‐1 Bla, the most common β‐lactamase. CDG‐3 can detect 10 colony‐forming units of the attenuated Mycobacterium bovis strain BCG in human sputum in the presence of high levels of contaminating β‐lactamases expressed by other clinically prevalent bacterial strains. In a trial with 50 clinical samples, CDG‐3 detected tuberculosis with 90 % sensitivity and 73 % specificity relative to Mtb culture within one hour, thus demonstrating its potential as a low‐cost point‐of‐care test for use in resource‐limited areas.
ETX2514 is a Broad-Spectrum Β-Lactamase Inhibitor for the Treatment of Drug-Resistant Gram-negative Bacteria Including Acinetobacter Baumannii

Thomas F. Durand-Réville,Satenig Guler,Janelle Comita-Prevoir,Brendan Chen,Neil Bifulco,Hoan Huynh,Sushmita Lahiri,Adam B. Shapiro,Sarah M. McLeod,Nicole M. Carter,Samir H. Moussa,Camilo Velez-Vega,Nelson B. Olivier,Robert McLaughlin,Ning Gao,Jason Thresher,Tiffany Palmer,Beth Andrews,Robert A. Giacobbe,Joseph V. Newman,David E. Ehmann,Boudewijn de Jonge,John O'Donnell,John P. Mueller,Rubén A. Tommasi,Alita A. Miller

DOI: https://doi.org/10.1038/nmicrobiol.2017.104

IF: 28.3

2017-01-01

Nature Microbiology

Abstract:Multidrug-resistant (MDR) bacterial infections are a serious threat to public health. Among the most alarming resistance trends is the rapid rise in the number and diversity of β-lactamases, enzymes that inactivate β-lactams, a class of antibiotics that has been a therapeutic mainstay for decades. Although several new β-lactamase inhibitors have been approved or are in clinical trials, their spectra of activity do not address MDR pathogens such as Acinetobacter baumannii. This report describes the rational design and characterization of expanded-spectrum serine β-lactamase inhibitors that potently inhibit clinically relevant class A, C and D β-lactamases and penicillin-binding proteins, resulting in intrinsic antibacterial activity against Enterobacteriaceae and restoration of β-lactam activity in a broad range of MDR Gram-negative pathogens. One of the most promising combinations is sulbactam–ETX2514, whose potent antibacterial activity, in vivo efficacy against MDR A. baumannii infections and promising preclinical safety demonstrate its potential to address this significant unmet medical need. Development of a broad-spectrum β-lactamase inhibitor capable of combatting multidrug-resistant pathogens, including Acinetobacter baumannii.
In Vitro Activity of Tetracycline Analogs against Multidrug-resistant and Extensive drug resistance Clinical Isolates of Mycobacterium tuberculosis

Qi Ouyang,Dachuan Lin,Guofang Deng,Zhihua Wen,Houming Liu,Hongzhen Li,Yi Cai,Xinchun Chen

DOI: https://doi.org/10.21203/rs.2.17754/v1

2019-11-27

Abstract:Abstract Background Multidrug-resistant tuberculosis (MDR-TB) has become a big threaten to global health . The current strategy for treatment of MDR-TB and extensive drug resistant tuberculosis (XDR-TB) is with low efficacy and high side effect. While new drug is fundamental for cure MDR-TB, repurposing the Food and Drug Administration (FDA)-approved drugs represents an alternative soluation with less cost.Methods The activity of 8 tetracycline-class antibiotics against mycobacterium tuberculosis ( M.tb ) were determined by Minimum Inhibitory Concentration (MIC) in vitro. A transposon M.smeg libraries was generated by using the Harm phage and then used to isolate the conditional growth mutants in doxycycline containing plate. 11 mutants were isolated and genomic DNAs were extracted using the cetyltrimethyl ammonium bromide (CTAB) method and analyzed by whole genome sequencing.Results We found that three of eight drugs efficiently inhibited mycobacteria growth under the peak plasma concentration in the human body. Further tests showed these three tetracycline analogs (demeclocycline, doxycycline and methacycline) had antimicrobial activity against seven clinical isolates, including MDR and XDR strains. Among them, Doxycycline had the lowest MICs in all mycobacteria strains tested in this study. By using a transposon library, we identify the insertion of transposon in two genes, porin and MshA, associate with the resistant to doxycycline.Conclusions Our findings show that tetracycline analogs such as doxycycline, has bactericidal activity against not only drug sensitive M.tb , but also clinical MDR and XDR strains, provided proof of concept to repurpose doxycycline to fight MDR-TB and XDR-TB. Further investigations are warranted to clarify the underlying mechanism and optimize the strategy in combination with other anti-TB drugs.
Whole-animal Imaging of Bacterial Infection Using Endoscopic Excitation of Β-Lactamase (Blac)-Specific Fluorogenic Probe

Fatemeh Nooshabadi,Hee-Jeong Yang,Yunfeng Cheng,Hexin Xie,Jianghong Rao,Jeffrey D. Cirillo,Kristen C. Maitland

DOI: https://doi.org/10.1117/12.2213820

2016-01-01

Abstract:Tuberculosis (TB), caused by Mycobacterium tuberculosis (Mtb), remains one of the most frequent causes of death worldwide. The slow growth rate of Mtb limits progress toward understanding tuberculosis including diagnosis of infections and evaluating therapeutic efficacy. Development of near-infrared (NIR) beta-lactamase (BlaC)-specific fluorogenic substrate has made a significant breakthrough in the whole-animal imaging to detect Mtb infection. The reporter enzyme fluorescence (REF) system using a BlaC-specific fluorogenic substrate has improved the detection sensitivity in whole-animal optical imaging down to similar to 10(4) colony forming units (CFU) of bacteria, about 100-fold improvement over recombinant strains. However, improvement of detection sensitivity is strongly needed for clinical diagnosis of early stage infection at greater tissue depth. In order to improve detection sensitivity, we have integrated a fiber-based microendoscpe into a whole-animal imaging system to transmit the excitation light from the fiber bundle to the fluorescent target directly and measure fluorescent level using BlaC-specific REF substrate in the mouse lung. REF substrate, CNIR800, was delivered via aerosol route to the pulmonary infected mice with M. bovis BCG strain at 24 hours post-infection and groups of mice were imaged at 1-4 hours post-administration of the substrate using the integrated imaging system. In this study we evaluated the kinetics of CNIR800 substrate using REF technology using the integrated imaging system. Integration of these technologies has great promise for improved detection sensitivity allowing pre-clinical imaging for evaluation of new therapeutic agents.
Compositions Et Procédés Pour Le Profilage De L'expression De Micro-Arn Dans Un Plasma D'un Cancer Colorectal

Zhaoyong Li,Ying Wu,Hongguang Zhu,Jian Li,Y. Ren

2010-01-01

Abstract:La presente invention concerne des compositions et des procedes de profilage de l'expression de micro-ARN (mi-ARN) dans un plasma d'un cancer colorectal. L'invention concerne notamment un kit de diagnostic de marqueurs moleculaires dans le sang pour le diagnostic du cancer colorectal, le suivi du traitement du cancer et/ou le traitement du cancer colorectal. Selon l'invention, le kit comprend une pluralite de molecules d'acide nucleique, chaque molecule d'acide nucleique codant pour une sequence de micro-ARN, une ou plusieurs molecules parmi la pluralite de molecules d'acide nucleique etant exprimees differemment dans un plasma d'un cancer colorectal et dans un plasma temoin sain, et la ou les molecules d'acide nucleique exprimees differemment representant ensemble une signature d'expression d'acides nucleiques qui est indicatrice de la presence d'un cancer colorectal. L'invention concerne egalement des procedes correspondants d'utilisation de telles signatures d'expression d'acides nucleiques pour identifier un cancer colorectal et pour la prevention ou le traitement d'une telle maladie. L'invention concerne enfin une composition pharmaceutique pour la prevention et/ou le traitement du cancer colorectal.
Evaluation of targeted sequencing for pathogen identification in bone and joint infections: a cohort study from China

Qiang Zhang,Yonghua Ding,Quanzhong Ren,Feng Zhang,Guoqiang Lyu,Tongxin Lu,Zhen Song,Qing Wang,Yongxiang Cheng,Jing Wang,Hongcang Gu

DOI: https://doi.org/10.1186/s12941-024-00733-z

2024-08-22

Abstract:Purpose: Bone and joint tuberculosis (BJTB) is a distinct variant of tuberculosis in which clinical diagnosis often leads to relative misdiagnosis and missed diagnoses. This study aimed to evaluate the diagnostic accuracy of the targeted nanopore sequencing (TNPseq) assay for BJTB patients in China. Method: The study enrolled a cohort of 163 patients with suspected BJTB. Diagnostic testing was performed using the TNPseq assay on samples including punctured tissue, pus, and blood. The diagnostic accuracy of the TNPseq assay was then compared with that of the T-SPOT and Xpert MTB/RIF assays. Result: TNPseq exhibited superior performance in terms of accuracy, demonstrating a sensitivity of 76.3% (95% CI: 71.0-81.6%) and a specificity of 98.8% (95% CI: 93.5-100%) in clinical diagnosis. When evaluated against a composite reference standard, TNPseq demonstrated a sensitivity of 74.4% (95% CI: 69.3-79.5%) and a specificity of 98.8% (95% CI: 93.7-100%). These results exceed the performance of both the T-SPOT and Xpert MTB/RIF tests. Notably, TNPseq demonstrated high specificity and accuracy in puncture specimens, with a sensitivity of 75.0% (95% CI: 70.2-79.8%) and a specificity of 98.3% (95% CI: 92.7-100%), as well as in pus samples, with a sensitivity of 83.3% (95% CI: 78.6-88.1%) and a specificity of 100% (95% CI: 100-100%). Additionally, TNPseq facilitated the detection of mixed infection scenarios, identifying 20 cases of bacterial-fungal co-infection, 17 cases of bacterial-viral co-infection, and two cases of simultaneous bacterial-fungal-viral co-infection. Conclusion: TNPseq demonstrated great potential in the diagnosis of BJTB due to its high sensitivity and specificity. The ability of TNPseq to diagnose pathogens and detect drug resistance genes can also guide subsequent treatment. Expanding the application scenarios and scope of TNPseq will enable it to benefit more clinical treatments.
Synergistic oral beta-lactam combinations for treating tuberculosis

Diana H Quan,Trixie Wang,Elena Martinez,Hannah Y Kim,Vitali Sintchenko,Warwick J Britton,James A Triccas,Jan-Willem C Alffenaar

DOI: https://doi.org/10.1093/jambio/lxae255

2024-10-03

Abstract:Background: The enormous burden of tuberculosis (TB) worldwide is a major challenge to human health, but the costs and risks associated with novel drug discovery have limited treatment options for patients. Repurposing existing antimicrobial drugs offers a promising avenue to expand TB treatment possibilities. This study aimed to explore the activity and synergy of beta-lactams in combination with a beta-lactamase inhibitor, which have been underutilized in TB treatment to date. Methods: Based on inhibitory concentration, oral bioavailability, and commercial availability, seven beta-lactams (cefadroxil, tebipenem, cephradine, cephalexin, cefdinir, penicillin V, and flucloxacillin), two beta-lactamase inhibitors (avibactam and clavulanate), and three second-line TB drugs (moxifloxacin, levofloxacin, and linezolid) were selected for combination in vitro testing against Mycobacterium tuberculosis H37Rv. Resazurin assays and colony forming unit enumeration were used to quantify drug efficacy, Chou-Talalay calculations were performed to identify drug synergy and Chou-Martin calculations were performed to quantify drug dose reduction index. Results: The order of activity of beta-lactams was cefadroxil > tebipenem > cephradine > cephalexin > cefdinir > penicillin V > flucloxacillin. The addition of clavulanate improved beta-lactam activity to a greater degree than the addition of avibactam. As a result, avibactam was excluded from further investigations, which focused on clavulanate. Synergy was demonstrated for cefdinir/cephradine, cefadroxil/tebipenem, cefadroxil/penicillin V, cefadroxil/cefdinir, cephalexin/tebipenem, cephalexin/penicillin V, cephalexin/cefdinir, cephalexin/cephradine, and cefadroxil/cephalexin, all with clavulanate. However, combining beta-lactams with moxifloxacin, levofloxacin, or linezolid resulted in antagonistic effects, except for the combinations of penicillin V/levofloxacin, penicillin V/moxifloxacin, and cefdinir/moxifloxacin. Conclusions: Beta-lactam synergy may provide viable combination therapies for the treatment of TB.
Ultrafast, One-Step, Label-Based Biosensor Diagnosis Platform for the Detection of Mycobacterium tuberculosis in Clinical Applications

Xinggui Yang,Xu Chen,Junfei Huang,Yijiang Chen,Wenlin Zheng,Wei Chen,Huijuan Chen,Shiguang Lei,Shijun Li

DOI: https://doi.org/10.1021/acsinfecdis.2c00475

IF: 5.578

2023-03-16

ACS Infectious Diseases

Abstract:Tuberculosis (TB) is a chronic infectious disease caused by the etiological agent Mycobacterium tuberculosis (MTB). Because the majority of TB patients come from poor economic backgrounds, the development of a simple, specific, low-cost, and highly sensitive detection method for the pathogen is extremely important for the prevention and treatment of this disease. In the current study, an efficient detection method for visual, rapid, and highly sensitive detection of MTB utilizing multiplex loop-mediated isothermal amplification combined with a label-based lateral flow immunoassay biosensor (mLAMP-LFIA) was developed. Three specific primer sets targeting the MTB genes IS6110 and mpb64 were successfully designed and synthesized for the LAMP assay. The optimal reaction conditions for the mLAMP-LFIA assay were confirmed to be 67 °C for 40 min. The mLAMP amplicons were intuitively verified using the LFIA biosensor within 5 min. The entire process, including clinical sample processing, amplification reaction, and product verification, was completed within 80 min. The limit of detection of the mLAMP-LFIA assay established in the current study was 100 fg per reaction for the genomic DNA of MTB H37Rv. The analytical specificity of the mLAMP-LFIA assay was one hundred percent, and no cross-reactions with non-target strains were detected. Compared with the GeneXpert test, the sensitivity of mLAMP-LFIA for 148 clinical specimens was 100% (97/97), and the specificity was 98.04% (50/51) in the preliminary evaluation of the clinical application. Hence, the mLAMP-LFIA method, targeting the IS6110 and mpb64 genes, is an ultrafast, one-step, low-cost, and highly sensitive detection method that could be used as a screening and/or diagnostic tool for MTB in the clinical setting, basic science laboratories, and especially in resource-poor regions.

chemistry, medicinal,infectious diseases
Sequencing-based Detection of Drug-Resistant Mycobacterium Tuberculosis in Patients with Spinal Tuberculosis

Jianwei Si,Zhe Wang,Zili Wang,Haomin Li

DOI: https://doi.org/10.1007/s00402-012-1506-7

IF: 2.928

2012-01-01

Archives of Orthopaedic and Trauma Surgery

Abstract:Traditionally, bacterial cultures serve as the gold standard for the detection of drug resistance and can provide evidence for directing the treatment of tuberculosis. However, this method has a low positive rate and is time consuming, which significantly limits its wide application. Thus, in the present study, the genes associated with drug resistance were amplified and sequenced to determine the presence of drug-resistant mutations in Mycobacterium tuberculosis. In addition, to find a more sensitive, specific, rapid, and simple method for the detection of drug-resistant bacteria, this method was compared with traditional bacterial culture.
Potential Application of Digitally Linked Tuberculosis Diagnostics for Real-Time Surveillance of Drug-Resistant Tuberculosis Transmission: Validation and Analysis of Test Results

Kamela Charmaine Ng,Conor Joseph Meehan,Gabriela Torrea,Léonie Goeminne,Maren Diels,Leen Rigouts,Bouke Catherine de Jong,Emmanuel André

DOI: https://doi.org/10.2196/medinform.9309

2018-02-27

Abstract:Background: Tuberculosis (TB) is the highest-mortality infectious disease in the world and the main cause of death related to antimicrobial resistance, yet its surveillance is still paper-based. Rifampicin-resistant TB (RR-TB) is an urgent public health crisis. The World Health Organization has, since 2010, endorsed a series of rapid diagnostic tests (RDTs) that enable rapid detection of drug-resistant strains and produce large volumes of data. In parallel, most high-burden countries have adopted connectivity solutions that allow linking of diagnostics, real-time capture, and shared repository of these test results. However, these connected diagnostics and readily available test results are not used to their full capacity, as we have yet to capitalize on fully understanding the relationship between test results and specific rpoB mutations to elucidate its potential application to real-time surveillance. Objective: We aimed to validate and analyze RDT data in detail, and propose the potential use of connected diagnostics and associated test results for real-time evaluation of RR-TB transmission. Methods: We selected 107 RR-TB strains harboring 34 unique rpoB mutations, including 30 within the rifampicin resistance-determining region (RRDR), from the Belgian Coordinated Collections of Microorganisms, Antwerp, Belgium. We subjected these strains to Xpert MTB/RIF, GenoType MTBDRplus v2.0, and Genoscholar NTM + MDRTB II, the results of which were validated against the strains' available rpoB gene sequences. We determined the reproducibility of the results, analyzed and visualized the probe reactions, and proposed these for potential use in evaluating transmission. Results: The RDT probe reactions detected most RRDR mutations tested, although we found a few critical discrepancies between observed results and manufacturers' claims. Based on published frequencies of probe reactions and RRDR mutations, we found specific probe reactions with high potential use in transmission studies: Xpert MTB/RIF probes A, Bdelayed, C, and Edelayed; Genotype MTBDRplus v2.0 WT2, WT5, and WT6; and Genoscholar NTM + MDRTB II S1 and S3. Inspection of probe reactions of disputed mutations may potentially resolve discordance between genotypic and phenotypic test results. Conclusions: We propose a novel approach for potential real-time detection of RR-TB transmission through fully using digitally linked TB diagnostics and shared repository of test results. To our knowledge, this is the first pragmatic and scalable work in response to the consensus of world-renowned TB experts in 2016 on the potential of diagnostic connectivity to accelerate efforts to eliminate TB. This is evidenced by the ability of our proposed approach to facilitate comparison of probe reactions between different RDTs used in the same setting. Integrating this proposed approach as a plug-in module to a connectivity platform will increase usefulness of connected TB diagnostics for RR-TB outbreak detection through real-time investigation of suspected RR-TB transmission cases based on epidemiologic linking.
Proteomics study the potential targets for Rifampicin-resistant spinal tuberculosis

Yanling Wang,Shijie Yin,Shixiong Wang,Kuang Rong,Xiang-He Meng,Huashan Zhou,Luo Jiao,Da Hou,Zhongjing Jiang,Jun He,Zenghui Mao

DOI: https://doi.org/10.3389/fphar.2024.1370444

IF: 5.6

2024-04-15

Frontiers in Pharmacology

Abstract:Introduction: The escalating global surge in Rifampicin-resistant strains poses a formidable challenge to the worldwide campaign against tuberculosis (TB), particularly in developing countries. The frequent reports of suboptimal treatment outcomes, complications, and the absence of definitive treatment guidelines for Rifampicin-resistant spinal TB (DSTB) contribute significantly to the obstacles in its effective management. Consequently, there is an urgent need for innovative and efficacious drugs to address Rifampicin-resistant spinal tuberculosis, minimizing the duration of therapy sessions. This study aims to investigate potential targets for DSTB through comprehensive proteomic and pharmaco-transcriptomic analyses. Methods: Mass spectrometry-based proteomics analysis was employed to validate potential DSTB-related targets. PPI analysis confirmed by Immunohistochemistry (IHC) and Western blot analysis. Results: The proteomics analysis revealed 373 differentially expressed proteins (DEPs), with 137 upregulated and 236 downregulated proteins. Subsequent Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) analyses delved into the DSTB-related pathways associated with these DEPs. In the context of network pharmacology analysis, five key targets—human leukocyte antigen A chain (HLAA), human leukocyte antigen C chain (HLA-C), HLA Class II Histocompatibility Antigen, DRB1 Beta Chain (HLA-DRB1), metalloproteinase 9 (MMP9), and Phospholipase C-like 1 (PLCL1)—were identified as pivotal players in pathways such as "Antigen processing and presentation" and "Phagosome," which are crucially enriched in DSTB. Moreover, pharmaco-transcriptomic analysis can confirm that 58 drug compounds can regulate the expression of the key targets. Discussion: This research confirms the presence of protein alterations during the Rifampicin-resistant process in DSTB patients, offering novel insights into the molecular mechanisms underpinning DSTB. The findings suggest a promising avenue for the development of targeted drugs to enhance the management of Rifampicin-resistant spinal tuberculosis.

pharmacology & pharmacy
Triplex real-time PCR melting curve analysis for detecting Mycobacterium tuberculosis mutations associated with resistance to second-line drugs in a single reaction.

Qingyun Liu,Tao Luo,Jing Li,Jian Mei,Qian Gao

DOI: https://doi.org/10.1093/jac/dks509

2013-01-01

Journal of Antimicrobial Chemotherapy

Abstract:Resistance to anti-tuberculosis (TB) drugs has been a great challenge for global TB control. Limited tools have been developed to detect resistance to second-line drugs that are associated with extensively drug-resistant (XDR) TB. In this study we aimed to develop a simple and widely applicable assay for detecting mutations associated with second-line drug resistance in Mycobacterium tuberculosis. Three dually labelled probes targeting gyrA, rrs and the promoter of eis were designed to detect resistance to fluoroquinolones and second-line injectable agents (capreomycin, amikacin and kanamycin). A triplex reaction with all three probes and corresponding primers was first tested against 13 isolates with different mutations in the targeted regions. Then, the triplex assay was applied to 109 second-line drug-resistant isolates in a blind manner and the results were compared with the sequencing data. All mutations in the targeted regions of 13 representative isolates could be detected through significant T-m reductions of the corresponding probe compared with the wild-type control. The detection results with 109 isolates were 100 concordant with sequencing data. Twelve ofloxacin-resistant isolates were detected as heteroresistant, indicating the coexistence of mutant and wild-type strains or the existence of different gyrA mutations. We have developed a simple and widely applicable assay to detect second-line drug resistance of M. tuberculosis. This method, combined with assays for detecting first-line drug resistance, provides an efficient and reliable tool to diagnose multidrug-resistant TB and XDR-TB.
Accuracy of the GeneXpert® MRSA/SA SSTI test to diagnose methicillin-resistant Staphylococcus spp. infection in bone fixation and fusion and management of infected non-unions

Théo Martin,Pierre Martinot,Jean-Thomas Leclerc,Marie Titécat,Caroline Loïez,Julien Dartus,Alain Duhamel,Henri Migaud,Christophe Chantelot,Barthélémy Lafon Desmurs,Thomas Amouyel,Eric Senneville

DOI: https://doi.org/10.1016/j.otsr.2024.103820

2024-01-23

Abstract:Introduction: The GeneXpert® MRSA/SA SSTI (Methicillin Resistant Staphylococcus aureus / S. aureus skin and soft tissue infection) PCR test allows early detection of methicillin resistance in staphylococci. This test was developed for skin infections and has been evaluated for prosthetic joint infections but, to our knowledge, has not been evaluated for hardware infections outside of arthroplasties. Furthermore, we conducted a retrospective study in patients with non-prosthetic osteosynthesis hardware aiming: 1) to identify the diagnostic values of the PCR test compared to conventional cultures and the resulting rate of appropriate antibiotic therapy. 2) to identify the rate of false negative (FN) results, 3) to identify and compare the rates of failure of infectious treatment (FN versus others) 4) to search for risk factors for FN of the PCR test. Hypothesis: The PCR test allowed early and appropriate targeting of antibiotic therapy. Material and methods: The results of PCR tests and conventional cultures for osteoarticular infections of non-prosthetic hardware over four years (2012-2016) were compared to identify the diagnostic values of using the results of conventional culture as a reference and the rate of appropriate antibiotic therapies. Infectious management failures between the results of the FN group and the others were compared, and variables associated with a FN of the PCR test were identified. Results: The analysis of 419 PCR tests allowed us to establish a sensitivity of 42.86%, a specificity of 96.82%, a positive predictive value of 60% and a negative predictive value of 93.83%. Using the results of the PCR test for the targeting of postoperative antibiotic therapy, it was suitable for staphylococcal coverage in 90.94% (381/419). The rates of patients for whom infectious treatment failed were not significantly different between the FN group and the other patients (20.8% versus 17.7%, respectively; Hazard Ratio = 1.12 (95%CI 0.47-2.69, p = 0.79)). A skin opening during the initial trauma (p = 0.005) and a polymicrobial infection were significantly associated with a risk of FN from the PCR test (p < 0.001). Conclusion: The PCR test makes it possible to reduce the duration of empirical broad-spectrum antibiotic therapy during the treatment of an infection of osteosynthesis hardware but causes a lack of antibiotic coverage in 9.06% of cases. Level of evidence: III; Diagnostic case control study. Résumé Introduction : Le test PCR GeneXpert® MRSA/SA SSTI (Methicillin Resistant Staphylococcus aureus / S. aureus skin and soft tissue infection) (test PCR) permet la détection précoce de la résistance à la méticilline des staphylocoques. Ce test a été mis au point pour les infections cutanées et a été évalué pour les infections prothétiques mais, à notre connaissance, n'a pas été évalué pour les infections sur matériel en dehors des arthroplasties. Aussi, nous avons mené une étude rétrospective chez des patients porteurs d'un matériel d'ostéosynthèse non prothétique avec comme objectif principal d'identifier les valeurs diagnostiques du test PCR comparativement aux cultures conventionnelles et le taux d'antibiothérapie adaptée qui en découle. Les objectifs secondaires étaient : 1) d'identifier le taux de résultats faux négatifs, 2) d'identifier et comparer les taux d'échec de prise en charge infectieuse (FN versus les autres) 3) de rechercher les facteurs de risque de FN du test PCR. Hypothèse : Le test PCR permettait une adaptation précoce et adaptée de l'antibiothérapie. Matériel et Méthodes : Les résultats des tests PCR et des cultures conventionnelles pour des infections ostéo-articulaires sur matériel non prothétiques sur quatre ans (2012-2016) ont été comparés pour identifier les valeurs diagnostiques du utilisant les résultats de la culture conventionnelle comme référence et le taux d'antibiothérapies adaptées. Les échecs de prise en charge infectieuse entre les résultats du groupe FN et les autres ont été comparés et des variables associées à un faux négatif du test PCR ont été recherchées. Résultats : L'analyse de 419 tests PCR nous a permis d'établir une sensibilité de 42,86%, une spécificité de 96,82%, une valeur prédictive positive de 60% et une valeur prédictive négative de 93,83%. En utilisant les résultats du test PCR pour l'adaptation de l'antibiothérapie postopératoire d'attente, celle-ci était adaptée pour la couverture des staphylocoques dans 90,94% (381/419). Les taux de patients pour lesquels la prise en charge infectieuse a échoué n'étaient pas significativement différents entre le groupe FN et les autres patients (20,8% versus 17,7%, respectivement ; Hazard Ratio = 1,12 (IC95 0,47-2,69, p = 0,79)). Une ouverture cutanée lors du traumatisme initial (p= 0,005) et une infection polymicrobi -Abstract Truncated-

surgery,orthopedics
A Color-Reaction-Based Biochip Detection Assay for RIF and INH Resistance of Clinical Mycobacterial Specimens

Wenfei Xue,Jingfu Peng,Xiaoli Yu,Shulin Zhang,Boping Zhou,Danqing Jiang,Jianbo Chen,Bingbing Ding,Bin Zhu,Yao Li

DOI: https://doi.org/10.4014/jmb.1501.01015

2016-01-01

Journal of Microbiology and Biotechnology

Abstract:The widespread occurrence of drug-resistant Mycobacterium tuberculosis places importance on the detection of TB (tuberculosis) drug susceptibility. Conventional drug susceptibility testing (DST) is a lengthy process. We developed a rapid enzymatic color-reaction-based biochip assay. The process included asymmetric multiplex PCR/templex PCR, biochip hybridization, and an enzymatic color reaction, with specific software for data operating. Templex PCR (tem- PCR) was applied to avoid interference between different primers in conventional multiplex- PCR. We applied this assay to 276 clinical specimens (including 27 sputum, 4 alveolar lavage fluid, 2 pleural effusion, and 243 culture isolate specimens; 40 of the 276 were non-tuberculosis mycobacteria specimens and 236 were M. tuberculosis specimens). The testing process took 4.5 h. A sensitivity of 50 copies per PCR was achieved, while the sensitivity was 500 copies per PCR when tem-PCR was used. Allele sequences could be detected in mixed samples at a proportion of 10%. Detection results showed a concordance rate of 97.46% (230/236) in rifampicin resistance detection (sensitivity 95.40%, specificity 98.66%) and 96.19% (227/236) in isoniazid (sensitivity 93.59%, specificity 97.47%) detection with those of DST assay. Concordance rates of testing results for sputum, alveolar lavage fluid, and pleural effusion specimens were 100%. The assay provides a potential choice for TB diagnosis and treatment.
Inhibitors of Bacterial Efflux Pumps as Adjuvants in Antibiotic Treatments and Diagnostic Tools for Detection of Resistance by Efflux

Françoise Van Bambeke,Jean-Marie Pagès,Ving J Lee,Francoise Bambeke,Jean-Marie Pages,Ving Lee

DOI: https://doi.org/10.2174/157489106777452692

2006-06-01

Abstract:Active efflux is a widespread mechanism for bacterial resistance to antibiotics, which contributes to poor intrinsic susceptibility, cross-resistance to structurally diverse classes of drugs, or selection of other mechanisms of resistance. Thus, inhibition of efflux pumps appears to be (i) a promising strategy for restoring the activity of existing antibiotics, and (ii) a useful method to detect the presence of efflux determinants in clinical isolates. Structurally dissimilar classes of inhibitors have been patented in the last decade, some are analogs of antibiotic substrates [tetracyclines, quinolones or aminoglycosides] and others, new chemical entities [including substituted indoles, ureas, aromatic amides, piperidinecarboxylic acids, alkylamino- or alkoxyquinolines, peptidomimetics, and pyridopyrimidines]. Their spectrum of activity, in terms of antibiotics and bacteria, differ significantly. Narrow spectrum inhibitors are of prime interest as diagnostic tools, while broad spectrum inhibitors are expected for adjuvant therapies. Apart from (i) a peptidomimetic inhibitor of Mex pumps in Pseudomonas aeruginosa (MC-04,124), for which efficacy was evaluated in animal models, and (ii) a piperidinecarboxylic acid inhibitor of fluoroquinolone efflux in Gram-positive (VX-710), which was safely administered to humans, most of these products have only demonstrated their activity in vitro, so further investigations are needed to evaluate their clinical potential.
Screening of Compounds for Anti-tuberculosis Activity, and in vitro and in vivo Evaluation of Potential Candidates

Wei Zhou,Bing Yang,Yanyan Zou,Khaista Rahman,Xiaojian Cao,Yingying Lei,Ren Lai,Zhen F. Fu,Xi Chen,Gang Cao

DOI: https://doi.org/10.3389/fmicb.2021.658637

IF: 5.2

2021-06-30

Frontiers in Microbiology

Abstract:Tuberculosis (TB) is a debilitating infectious disease responsible for more than one million deaths per year. The emergence of drug-resistant TB poses an urgent need for the development of new anti-TB drugs. In this study, we screened a library of over 4,000 small molecules and found that orbifloxacin and the peptide AK15 possess significant bactericidal activity against Mycobacterium tuberculosis ( Mtb ) in vitro . Orbifloxacin also showed an effective ability on the clearance of intracellular Mtb and protect mice from a strong inflammatory response but not AK15. Moreover, we identified 17 nucleotide mutations responsible for orbifloxacin resistance by whole-genome sequencing. A critical point mutation (D94G) of the DNA gyrase ( gyrA ) gene was found to be the key role of resistance to orbifloxacin. The computational docking revealed that GyrA D94G point mutation can disrupt the orbifloxacin–protein gyrase interactions mediated by magnesium ion bridge. Overall, this study indicated the potential ability of orbifloxacin as an anti-tuberculosis drug, which can be used either alone or in combination with first-line antibiotics to achieve more effective therapy on TB.

microbiology
Targeted next-generation sequencing of Mycobacterium tuberculosis from patient samples: lessons learned from high drug-resistant burden clinical settings in Bangladesh

Mohammad Khaja Mafij Uddin,Andrea Maurizio Cabibbe,Rumana Nasrin,Arash Ghodousi,Fahim Alam Nobel,S. M. Mazidur Rahman,Shahriar Ahmed,Md. Fahim Ather,S. M. Abdur Razzaque,Md. Abu Raihan,Pronab Kumar Modak,Jean Luc Berland,Wayne Van Gemert,Sardar Munim Ibna Mohsin,Daniela Maria Cirillo,Sayera Banu

DOI: https://doi.org/10.1080/22221751.2024.2392656

2024-08-27

Emerging Microbes & Infections

Abstract:Lack of appropriate early diagnostic tools for drug-resistant tuberculosis (DR-TB) and their incomplete drug susceptibility testing (DST) profiling is concerning for TB disease control. Existing methods, such as phenotypic DST (pDST), are time-consuming, while Xpert MTB/RIF (Xpert) and line probe assay (LPA) are limited to detecting resistance to few drugs. Targeted next-generation sequencing (tNGS) has been recently approved by WHO as an alternative approach for rapid and comprehensive DST. We aimed to investigate the performance and feasibility of tNGS for detecting DR-TB directly from clinical samples in Bangladesh. pDST, LPA and tNGS were performed among 264 sputum samples, either rifampicin-resistant (RR) or rifampicin-sensitive (RS) TB cases confirmed by Xpert assay. Resistotypes of tNGS were compared with pDST, LPA and composite reference standard (CRS, resistant if either pDST or LPA showed a resistant result). tNGS results revealed higher sensitivities for rifampicin (RIF) (99.3%), isoniazid (INH) (96.3%), fluoroquinolones (FQs) (94.4%), and aminoglycosides (AMGs) (100%) but comparatively lower for ethambutol (76.6%), streptomycin (68.7%), ethionamide (56.0%) and pyrazinamide (50.7%) when compared with pDST. The sensitivities of tNGS for INH, RIF, FQs and AMGs were 93.0%, 96.6%, 90.9%, and 100%, respectively and the specificities ranged from 91.3 to 100% when compared with CRS. This proof of concept study, conducted in a high-burden setting demonstrated that tNGS is a valuable tool for identifying DR-TB directly from the clinical specimens. Its feasibility in our laboratory suggests potential implementation and moving tNGS from research settings into clinical settings.

immunology,infectious diseases,microbiology

Substrats De Bêta-Lactamases Et Leurs Procédés D'utilisation Dans Le Diagnostic De La Tuberculose

High-throughput fluorescent screening of β-lactamase inhibitors to improve antibiotic treatment strategies for tuberculosis

Compositions et procédés visant à potentialiser une activité antibiotique

Rapid point-of-care detection of the tuberculosis pathogen using a BlaC-specific fluorogenic probe

Fluorogenic Probes with Substitutions at the 2 and 7 Positions of Cephalosporin Are Highly BlaC‐Specific for Rapid Mycobacterium Tuberculosis Detection

ETX2514 is a Broad-Spectrum Β-Lactamase Inhibitor for the Treatment of Drug-Resistant Gram-negative Bacteria Including Acinetobacter Baumannii

In Vitro Activity of Tetracycline Analogs against Multidrug-resistant and Extensive drug resistance Clinical Isolates of Mycobacterium tuberculosis

Whole-animal Imaging of Bacterial Infection Using Endoscopic Excitation of Β-Lactamase (Blac)-Specific Fluorogenic Probe

Compositions Et Procédés Pour Le Profilage De L'expression De Micro-Arn Dans Un Plasma D'un Cancer Colorectal

Evaluation of targeted sequencing for pathogen identification in bone and joint infections: a cohort study from China

Synergistic oral beta-lactam combinations for treating tuberculosis

Ultrafast, One-Step, Label-Based Biosensor Diagnosis Platform for the Detection of Mycobacterium tuberculosis in Clinical Applications

Sequencing-based Detection of Drug-Resistant Mycobacterium Tuberculosis in Patients with Spinal Tuberculosis

Potential Application of Digitally Linked Tuberculosis Diagnostics for Real-Time Surveillance of Drug-Resistant Tuberculosis Transmission: Validation and Analysis of Test Results

Proteomics study the potential targets for Rifampicin-resistant spinal tuberculosis

Triplex real-time PCR melting curve analysis for detecting Mycobacterium tuberculosis mutations associated with resistance to second-line drugs in a single reaction.

Accuracy of the GeneXpert® MRSA/SA SSTI test to diagnose methicillin-resistant Staphylococcus spp. infection in bone fixation and fusion and management of infected non-unions

A Color-Reaction-Based Biochip Detection Assay for RIF and INH Resistance of Clinical Mycobacterial Specimens

Inhibitors of Bacterial Efflux Pumps as Adjuvants in Antibiotic Treatments and Diagnostic Tools for Detection of Resistance by Efflux

Screening of Compounds for Anti-tuberculosis Activity, and in vitro and in vivo Evaluation of Potential Candidates

Targeted next-generation sequencing of Mycobacterium tuberculosis from patient samples: lessons learned from high drug-resistant burden clinical settings in Bangladesh